Sepsis is a severe, life-threatening condition caused by an abnormal host response to infection, which includes systemic inflammation, oxidative stress, and increasing organ dysfunction. It is frequently associated with bacterial, viral, fungal, or parasite infections, as well as non-infectious illnesses like trauma and pancreatitis. It remains a primary cause of mortality in hospitals, with rates nearing 40% in severely ill patients. pathophysiological, excessive cytokine release (e.g., TNFα, IL-6, IL-1β) and reactive oxygen/nitrogen species lead to mitochondrial injury, immunosuppression, and multiple organ failure. Sepsis diagnosis is guided byNEWS2 & a SOFA score ≥2, hypotension, and elevated lactate, while worsening SOFA scores predict poor outcomes. Standard management focusses on early antibiotic therapy, fluid resuscitation, and vasoactive support. Standard anti-inflammatory methods using steroidal or non-steroidal medicines may show little efficacy to improve the patient's clinical outcomes. Adjunctive antioxidant therapies, including vitamins C and E, NAC, and melatonin, have demonstrated reductions in oxidative stress and organ dysfunction. Nicotinamide (NAM) (vitamin B3), a precursor of NAD+/NADP+ critical for energy metabolism and cellular repair, has emerged as a potential therapeutic candidate due to its ability to attenuate cytokine production, modulate immune responses, and mitigate oxidative damage. Usual dose of NAM (500mg-1500mg per day) is generally safe. A dose of 1000 mg was found to be safe and effective in reducing the circulating inflammatory cytokines showing a good profile as an anti-inflammatory adjunct therapy. Higher than usual NAM dose can increase the likelihood of adverse effects, such as diarrhea, increased liver enzymes (rarely occurring at doses exceeding 3 grams per day), symptoms of thrombocytopenia (including increased bruising and bleeding), and stomach upset.
Since the role of NAM as adjunct therapy in sepsis management is not yet established, further large-scale clinical studies are recommended to establish its efficacy and safety in sepsis management.
The aim of our study is to evaluate the efficacy and safety of the addition of Nicotinamide (1000mg oral tablet) as an adjunct therapy to improve the outcome of septic patients.

Start Date01 Jul 2026

Sponsor / Collaborator

Ain Shams University

CTRI/2026/05/111469

/ Not yet recruitingPhase 4

A single arm clinical study to evaluate the anti-sebum activity of the 10 Percent Niacinamide Face serum with 2 Percent Zinc PCA - NIL

Start Date08 Jun 2026

Sponsor / Collaborator-

NCT07585006

/ RecruitingPhase 1IIT

Comparative Evaluation of Nicotine Analogs

This phase I trial compares electronic cigarette (EC) user preferences and smoking behaviors of nicotine analogs to nicotine to improve the understanding of nicotine analog addictiveness. Over the last ten years, EC use has become a major concern due to its increased use among adolescents and young adults. Though progress has been made in regulating nicotine containing products, some companies have shifted toward producing products containing nicotine analogs. ECs are battery-powered electronic devices designed to atomize a nicotine (the poisonous chemical found in tobacco)-containing liquid solution for inhalation in a manner that simulates smoking a tobacco cigarette. When nicotine enters the body, it causes an increased heart rate and use of oxygen by the heart, and a sense of well-being and relaxation. Nicotine analogs are compounds that are similar to nicotine in their chemical structure. Some nicotine analogs have been shown to have nicotine-like effects; however, more research is needed to prove they function similarly to nicotine and/or have similar effects. Comparing EC user preferences and smoking behaviors of nicotine analogs to nicotine may help improve the understanding of nicotine analog addictiveness.
Additionally, combustible cigarette smoking is well-known to have deleterious effects on cardiovascular health. High blood pressure is one of the major health consequences of cigarette smoking and can increase the risk of hypertension, heart attack, and stroke. Although ECs have been marketed as a less harmful alternative to cigarette smoking, clinical trials have shown that vaping ECs can also lead to acute increases in blood pressure and heart rate. Nicotine can alter vascular reactivity by promoting the release of vasoconstrictors and suppressing the production of vasodilators. No research has examined how the synthetic nicotine in ECs affects hemodynamics, vascular health, and endothelial function. Assessing acute cardiovascular responses to nicotine analogs is therefore critical to enhancing our understanding of the potential cardiovascular risks associated with vaping ECs containing synthetic nicotine.

Start Date29 May 2026

Sponsor / Collaborator

Ohio State University Comprehensive Cancer Center

100 Clinical Results associated with Nicotinamide

100 Translational Medicine associated with Nicotinamide

100 Patents (Medical) associated with Nicotinamide

12,185

Literatures (Medical) associated with Nicotinamide

01 Oct 2026·LIFE SCIENCES

Targeting PARP1-dependent parthanatos in Alzheimer's disease: Mechanisms and therapeutic opportunities

Review

Author: Al-Gareeb, Ali I ; Al-Kuraishy, Hayder M ; Batiha, Gaber El-Saber ; Alameen, Ayman Ali Mohammed ; Albuhadily, Ali K ; Abdelaziz, Ahmed M

Alzheimer's disease (AD) is the predominant cause of dementia globally. This review clarifies the dual function of poly(ADP-ribose) polymerase 1 (PARP1) in AD pathogenesis, emphasizing its role in mediating parthanatos, a unique caspase-independent cell death mechanism. We analyze contemporary literature regarding PARP1 expression, parthanatos signaling, and pharmaceutical treatments in AD models. In addition, PARP1 exhibits context-dependent duality: its physiological nuclear expression in hippocampus neurons is essential for memory consolidation and decreases early in cognitive impairment, suggesting a correlative association with synaptic malfunction. In contrast, overactivity of PARP1 resulting from Aβ-induced oxidative stress and DNA damage induces neurodegeneration via multiple pathways, including NAD+/ATP exhaustion leading to metabolism collapse, creation of the AIF-MIF complex promoting parthanatos, NF-κB-induced neuroinflammation, dysregulation of mitophagy, and disruption of the neuroprotective SIRT1 signaling pathway. The overactivity contributes to a positive feedback loop, where PARP1 intensifies Aβ and tau protein accumulation while simultaneously disrupting the BBB. In preclinical models of AD, genetic knockout, pharmacologic agents such as PJ34 and MC2050, or precursors of NAD⁺ such as nicotinamide and NMN attenuate Aβ deposition, normalize metabolism, and ameliorate cognitive decline. The PARP1/parthanatos pathway is at the center of the confluence of oxidative stress, DNA damage, metabolism disorder, and neuroinflammation in AD. Metformin and other PARP1 inhibitors offer intriguing treatment options. PARP1's cell-type- and intracellular location-dependent activity necessitates careful consideration of context, dose, and disease stage while developing therapies. The present understanding in this review could inform future research on PARP1 regulation in AD clinical practice.

01 Oct 2026·EUROPEAN JOURNAL OF PHARMACEUTICS AND BIOPHARMACEUTICS

A smarter dermal filler: Antimicrobial protection and collagen stimulation with niacinamide

Article

Author: Applegate, Lee Ann ; Porcello, Alexandre ; Perron, Karl ; Jordan, Olivier ; Schelker, Cindy ; Laurent, Alexis Emmanuel ; Sublet, Emmanuelle ; Marques, Cintia ; Patrulea, Viorica ; Santi Martignago, Cintia Cristina

Biological skin aging involves structural changes, including flattening of the epidermal-dermal junction and reduced collagen types I and III. Modern aesthetic medicine is shifting from volumetric enhancement toward regenerative dermal fillers, though risks of delayed inflammation or infection from post-procedural injections should be mitigated. Niacinamide is a well-established molecule that stimulates collagen synthesis, modulates inflammation and inhibits bacterial growth. We evaluated the biostimulatory, antimicrobial, anti-inflammatory, and safety profiles of a new niacinamide-enriched cross-linked hyaluronic acid dermal filler (HAR) compared to untreated controls and Belotero Balance® (commercial reference). Biostimulation was assessed ex vivo in human skin explants cultured for 8 days, using Masson's trichrome staining and collagen I/III immunostaining. Antibacterial activity against Gram-positive and Gram-negative bacterial models was assessed by monitoring growth, while anti-inflammatory properties were analyzed via TNF-α and IL-6 levels in LPS-stimulated macrophages. Safety and biocompatibility were evaluated against human dermal fibroblasts. HAR-treated explants displayed improved epidermal architecture, and a denser collagen type I network. HAR inhibited bacterial growth (∼90% Gram-negative; ∼50% Gram-positive), significantly lowered IL-6 and TNF-α levels, and showed excellent biocompatibility with high fibroblast viability and minimal hemolysis. These findings highlight HAR as a multifunctional dermal filler combining essential structural support with regenerative, antibacterial, and anti-inflammatory benefits.

01 Sep 2026·BRAIN RESEARCH BULLETIN

Nao Tan Qing exerts neuroprotection against traumatic brain injury via multi-targeted immunomodulation and neurorestoration

Article

Author: Liu, Zhiqiang ; Lin, Yuqi ; Li, Qianqian ; Liu, Yuhan ; Xiao, Rui ; Chen, Xuyi ; Zhang, Ni ; He, Renke

BACKGROUND:

Traumatic brain injury (TBI) is a devastating neurological disorder with long-term functional deficits and limited effective therapies, where secondary injury driven by dysregulated immunity and disrupted signaling is pathogenic; Nao Tan Qing (NTQ), a Chinese herbal formula guided by the traditional principle of "resolving phlegm and inducing resuscitation" for "brain collateral obstruction", shows neuroprotective potential, but its role and mechanism in TBI treatment remain unclear.

AIM:

This study aimed to systematically investigate the neuroprotective effects of NTQ against TBI model mice and elucidate its underlying molecular mechanisms.

METHODS:

A controlled cortical impact (CCI) mouse model of TBI was established, and animals received NTQ treatment for 28 consecutive days. NTQ's neuroprotective efficacy was comprehensively evaluated via behavioral tests (functional recovery), cerebral blood flow imaging (vascular integrity), and electromyography (neural activity). Post-treatment inflammatory levels in TBI mice were assessed by quantifying inflammatory cytokine expression using quantitative real-time PCR and detecting microglial activation via immunofluorescence. Mechanistic exploration integrated network pharmacology, transcriptomics and bioinformatics analyses to identify NTQ's active components, potential targets, and associated pathways in TBI.

RESULTS:

In vivo experiments demonstrated that NTQ significantly improved behavioral outcomes, restored cerebral blood flow, and enhanced neural activity in TBI mice. Concurrent with these functional benefits, NTQ robustly suppressed neuroinflammation, as evidenced by reduced pro-inflammatory cytokine expression and attenuated microglial activation. Integrated network pharmacology and transcriptomic analyses confirmed that NTQ acts primarily through immune regulation after TBI, modifying key immune-related molecules and pathways. Specifically, NTQ intervention elicited pronounced downregulation of immune-inflammatory mediators, including Cd3g, Cd5, Cd8a, Epcam, Slamf7, Il16, Il17r, Il18rap, Cxcl9, Cxcr6, Tnfsf11, and Tnfsf15. Further mechanistic dissection identified six putative bioactive constituents of NTQ, including nicotinamide, curcumin, baicalin, chrysin, daidzein, and apigenin, which may remodel the intracerebral immune microenvironment after TBI through three core pathways: amine ligand-binding receptors, nuclear receptor meta-pathways, and arachidonic acid metabolism.

CONCLUSION:

Taken together, our integrated analyses demonstrate that NTQ exerts neuroprotective effects in TBI by modulating immune responses and suppressing neuroinflammation, thereby establishing NTQ as a promising multi-target therapeutic agent for TBI.

News (Medical) associated with Nicotinamide

28 May 2026

·www.prnewswire.com

Nevisense detects skin barrier damage by chemicals used in household cleaning products in a new ex-vivo study

STOCKHOLM, May 28, 2026 /PRNewswire/ -- SciBase Holding AB ("SciBase") (STO: SCIB) , a leader in AI-based devices for detection and prevention in dermatology, announced today the publication of a scientific project with the Swiss Institute of Allergy and Asthma Research (SIAF) in Davos, Switzerland. Nevisense and its underlying Electrical Impedance Spectroscopy (EIS) technology were used to show that surfactants in household cleaning products disrupt the human skin barrier. In the study, human ex vivo skin samples were exposed to Sodium dodecyl sulfate (SDS), a surfactant in household cleaning products which is known to impair the barrier. Also, skin that was affected by SDS were treated with N-acetylcysteine (NAC) and nicotinamide (NAM) to promote recovery of skin barrier function. Nevisense was used in the study to detect the changes in the skin barrier and detected that short-term exposure to SDS rapidly disrupts human skin barrier integrity within minutes as well as the effect of NAC and NAM. Skin barrier research is an expanding area in dermatology. Disruption of skin barrier function plays a key role in the development and severity of e.g. contact dermatitis from chemical substances "We are happy to see that Nevisense and EIS-technology continue to provide value in this type of research. This study further strengthens the role of Nevisense as an effective research device and show the potential to become the state-of-the-art research tool within the skin barrier research," said Pia Renaudin, CEO of SciBase. The full results of the study have now been published in the scientific journal Allergy " Rapid Human Skin Barrier Disruption by Sodium Dodecyl Sulfate and Associated Molecular Mechanisms," - Li - Allergy, DOI: For additional information, please contact: Pia Renaudin, CEO, tel. +46732069802, e-mail: [email protected] Certified Advisor (CA): DNB Carnegie Investment Bank AB (publ) Phone: +46 8 588 68 570, E-mail: [email protected] About SciBase SciBase is a global medical technology company, specializing in early detection and prevention in dermatology. SciBase develops, manufactures, and commercializes Nevisense, a unique point-of-care platform that combines AI and advanced EIS technology to elevate diagnostic accuracy, ensuring proactive skin health management. Our commitment is to minimize patient suffering, allowing clinicians to improve and save lives through timely detection and intervention and reduce healthcare costs. Built on more than 20 years of research at Karolinska Institute in Stockholm, Sweden, SciBase is a leader in dermatological advancements. The company has been on the Nasdaq First North Growth Market exchange since June 2, 2015 and the company's Certified Adviser is Carnegie Investment Bank AB (publ). Learn more at . For press releases and financial reports visit: This information was brought to you by Cision The following files are available for download: 21% more press release views with Request a Demo

21 May 2026

·www.einpresswire.com

PDRN Moves From Korean Clinics to Daily Skincare as U.S. Demand Accelerates

As PDRN transitions from clinical injectables to consumer skincare in 2026, Korean Boba Capsule Cream combining PDRN, Vitamin C, and collagen is now on Amazon. LOS ANGELES, CA, UNITED STATES, May 20, 2026 / EINPresswire.com / -- For years, PDRN — polydeoxyribonucleotide, a DNA fragment derived from salmon — was an ingredient reserved for dermatology clinics in South Korea, administered through injectables and microneedling treatments to support skin regeneration, collagen synthesis, and tissue repair. In 2026, that is changing. A convergence of K-beauty innovation, consumer demand for science-backed skincare, and accessible formulation technology has moved PDRN from the clinic into the daily skincare routine. According to industry data, PDRN-based skincare products are growing at a 14.1% compound annual growth rate — more than double the rate of traditional cosmetics. Vogue identified PDRN and exosomes as the dominant K-beauty trend for 2026, noting that these ingredients "gained popularity in 2025, and experts anticipate this trend will continue to flourish in 2026 as these ingredients transition from clinical to consumer formats" (Source: Financial Content / MarketersMEdia – financialcontent.com/article/marketersmedia-2026-2-5-seoulceuticals-launches-industrys-first-pdrn-vitamin-c-serum-as-bio-regenerative-actives-dominate-2026-k-beauty). Beauty Independent confirmed in January 2026 that "PDRN has gone mainstream," naming it among the breakout ingredients defining skincare's direction this year (Source: Beauty Independent – beautyindependent.com/top-skincare-trends-2026-those-losing-sizzle). A PDRN Capsule Cream combining Salmon DNA PDRN, Vitamin C, Niacinamide, and Collagen Jelly is now available on Amazon, offering consumers access to this clinic-grade ingredient in an everyday moisturizer format. ABOUT PDRN PDRN works by activating the A2A adenosine receptor, which stimulates fibroblast activity and promotes collagen synthesis, wound healing, and tissue regeneration. Clinical studies have demonstrated PDRN increases dermal density by 8.67% and skin brightness by 4.88% within 28 days. Multiple peer-reviewed studies have demonstrated its ability to improve skin elasticity and reduce visible signs of aging. Originally developed for regenerative medicine applications, its crossover into topical skincare — particularly in South Korea — represents one of the more significant formulation developments in the beauty industry in recent years (Source: Korean Skincare Coach – koreanskincarecoach.com/blog/the-rise-of-pdrn-in-korean-skincare-benefits-uses-and-top-products). ABOUT THE PRODUCT The realori PDRN Capsule Cream is a pink jelly-gel moisturizer formulated with four key actives: PDRN with Salmon DNA to support skin regeneration and elasticity; Vitamin C for antioxidant protection and brightening; Niacinamide to address uneven tone and texture; and Collagen Jelly capsules for hydration and firmness. The boba-capsule texture is designed for fast absorption without clogging pores, making it suitable for oily, dry, and combination skin types. The formula is free of harsh alcohols, common allergens, fragrances, parabens, and sulfates, and is formulated for both day and night use. WHY SUMMER Summer UV exposure is now documented as the second-largest cause of skin damage after bleaching, with repeated UV exposure accelerating collagen degradation and uneven pigmentation — the precise concerns PDRN and Vitamin C are clinically studied to address. Dermatologists note that antioxidant and regenerative topicals applied consistently over four to eight weeks produce measurable improvement in skin texture, tone, and barrier resilience — making summer an appropriate time to begin a PDRN-based routine ahead of fall, when skin undergoes its natural repair cycle. The PDRN Capsule Cream is available now on Amazon . Myah Taylor REALORI Skincare email us here Legal Disclaimer: EIN Presswire provides this news content "as is" without warranty of any kind. We do not accept any responsibility or liability for the accuracy, content, images, videos, licenses, completeness, legality, or reliability of the information contained in this article. If you have any complaints or copyright issues related to this article, kindly contact the author above.

08 May 2026

·www.prnewswire.com

Duno Health launches the Youth & Vitality Daily Supplement

BELMONT, Calif., May 8, 2026 /PRNewswire/ -- Duno Health, Inc., a leading consumer health sciences company, announced the launch of Youth & Vitality, a new daily supplement formulated with NAD+ precursor and essential vitamins to support cellular renewal and whole body health. Continue Reading Product description Differences between discrete categorised variable of the entire sample population Modern Age Research: NAD+ supplementation is now being recognized as a way to support almost every aspect of cellular metabolism, and can be especially important for healthy aging, since NAD+ levels naturally decline with age (Table 1, 1). In fact, low NAD+ levels are thought to be one of the key hallmarks of aging, contributing to dysfunctional cellular metabolism, cellular senescence, and dysregulated immune responses—so-called "inflammaging"—and have been found to be associated with aging-related disorders. Addressing this decline using supplementation with NAD+ precursors has become a hot topic in the aging-related disease prevention and longevity fields and is a primary focus for Duno. Clinical Tested Results: Youth & Vitality contains nicotinamide, a NAD+ precursor that has decades of clinical trial data showing its safety and effectiveness at boosting NAD+ levels in humans. It also functions in reducing the risk for certain skin cancers and in addressing some inflammatory conditions (2). By combining nicotinamide with key B vitamins, Youth & Vitality aims to promote cellular energy metabolism and DNA repair, and to support health benefits including cardiovascular health, neuroprotection, hormonal and sexual health and anti-aging effects in the skin. Focus on Everyday health: Cardiovascular disease is a major cause of age-associated disease and healthcare costs, yet experts believe a majority of cases could be prevented by lifestyle changes (3). Youth & Vitality supports cardiovascular health by helping to lower levels of homocysteine, a molecule known as a biomarker for cardiovascular disease risk (4,5). Our formula includes vitamin B6, vitamin B12, and folic acid, a combination that has been shown to significantly and synergistically reduce homocysteine levels (6). Cardiovascular health is closely associated with brain health and risk of developing neurodegenerative disease or dementia, as well as other conditions such as chronic kidney disease and erectile dysfunction. Unsurprisingly, high homocysteine levels have also been associated with these diseases (4,7,8）, and are thought to contribute to oxidative stress that worsens the progression of disease. By combating high homocysteine levels, Youth & Vitality synergistically addresses aging across major organ systems. Youth & Vitality is formulated based on the latest research into human health and longevity, to balance the multifaceted benefits of each ingredient. Recent preclinical studies have shown that vitamins B3 and B6 can stimulate muscle stem cell expansion and enhance regenerative capacity during aging (9). There is also evidence that vitamins B6 and B12 help to increase the synthesis of testosterone (10). Duno Health has studied the key hallmarks of aging across levels of analysis, from interconnected cellular pathways to tissue-wide effects to the mechanisms underlying systemic disease. Thus this product is designed to support multiple key aspects of cellular metabolism and help control homocysteine levels, creating the foundations of healthy function across the body's organ systems and truly support healthspan. Youth & Vitality from DUNO HEALTH is specially designed and formulated blend of muti-vitamins Bs support clinically studied markers of health aging: Boosting NAD+ (nicotinamide adenine dinucleotide) Reducing HCY (homocysteine) Stimulate muscle stem cell expansion Promote sexual health If you're approaching 50 or older, regular monitoring and management of homocysteine levels can play a key role in reducing risks of atherosclerosis , blood clots , Heart attack , Stroke , and supporting long-term health. To test its effectiveness, please have your blood drawn and homocysteine levels measured on the day before taking the supplement and the day after completing exactly one month （ 30 days ） of treatment. Submit both of your test reports, and you will receive a $20 discount when purchasing two more bottles. This discount is valid until August 31, 2026. For more details or buy and test it, please visit . Contact Phone: 650-977-9992. SOURCE Duno Health 21% more press release views with Request a Demo

100 Deals associated with Nicotinamide

External Link

KEGG	Wiki	ATC	Drug Bank
D00036	Nicotinamide	A11HA01	DB02701

R&D Status

Approved

10 top approved records.

to view more data

Indication	Country/Location	Organization	Date
Arrhythmias, Cardiac	China	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Coronary Artery Disease	China	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Myocarditis	China	Shanxi Taisheng Pharmaceutical Co., Ltd.	10 Mar 2006
Vitamin B Deficiency	China	China Resources Double-Crane Pharmaceutical Co., Ltd.	01 Jan 1996
Pellagra	Japan	Catalent Japan KK	27 Oct 1961
Acne Vulgaris	-	-	-

Developing

10 top R&D records.

to view more data

Indication	Highest Phase	Country/Location	Organization	Date
Chronic Kidney Diseases	Phase 2	Germany	MEDICE Arzneimittel Pütter GmbH & Co. KG	01 Aug 2010
Hyperphosphatemia	Phase 2	Germany	MEDICE Arzneimittel Pütter GmbH & Co. KG	01 Aug 2010
Liver Diseases, Alcoholic	Preclinical	China	Zhejiang Chinese Medical University	22 May 2025

Clinical Result

Indication

Phase

Evaluation

View All Results

Study	Phase	Population	Analyzed Enrollment	Group	Results	Evaluation	Publication Date


NCT03268902 (Early Life Interventions for Childhood Growth and Development in Tanzania, Pubmed \| Am J Clin Nutr)	Phase 2/3	Vitamin B Deficiency	1,173	Nicotinamide 250 mg/d	qzxutsxxpu(yfjrvptsru) = eofhpbtrvm xmhwjmwyuu (xyaxmxbmfy ) View more	Positive	01 Aug 2026
				Placebo	qzxutsxxpu(yfjrvptsru) = xroaponpqy xmhwjmwyuu (xyaxmxbmfy ) View more
NCT03061474 (NEAT, Pubmed \| Alzheimers Res Ther)	Phase 2	Alzheimer Disease pTau231	47	Nicotinamide 1500 mg PO BID	ewrxhcjsim(ylhgwmycoz) = bnlzytmciq vlupizpago (enrpshvrcl ) View more	Negative	11 Mar 2025
				Placebo	ltrjvtsbxq(drhbdqelwm) = whbajwjett eqlqpqnxwp (rifhickaob )
NCT02416739 (Pubmed) Manual	Phase 2	EGFR Mutation Lung Cancer EGFR Mutation	110	Nicotinamide	etaxxtekmr(ojsslxgujh) = ysnlvwjsge iabnicgvvy (rkgzbpfcex, 10.4 - 18.3) View more	Positive	09 Apr 2024
				Placebo	etaxxtekmr(ojsslxgujh) = ungptkklsb iabnicgvvy (rkgzbpfcex, 9.0 - 13.2) View more
NCT02416739 (AACR2024) Manual	Phase 2	EGFR Mutation Lung Cancer EGFR Mutation	110	Nicotinamide	plobeddoey(giquksjygz) = efeplahbpo jzwqjqlauk (hqbvarenxe, 10.4 - 18.3) View more	Positive	05 Apr 2024
				Placebo	plobeddoey(giquksjygz) = pidpfnklwl jzwqjqlauk (hqbvarenxe, 9.0 - 13.2) View more
NCT02258074 (COMBINE trial, Pubmed \| Kidney360)	Phase 2	Chronic Kidney Diseases interleukin-6 \| C-reactive protein	127	Nicotinamide and Lanthanum Carbonate	jtyukpzybp(vytpujgekk) = xwsibnfdzn amcuuinavd (qzlytwerxs ) View more	Positive	04 Apr 2024
				Placebo	jtyukpzybp(vytpujgekk) = rvvduseutw amcuuinavd (qzlytwerxs ) View more
NCT03136705 (CTgov)	Phase 1	-	39	Lanthanum Carbonate+Nicotinamide (Lanthanum + Nicotinamide)	fxpvjsntcy(tehrvbanps) = nlzudkhhgn rfqafvlndd (jcgtxfdrom, bxprzxfwqw - hxmvyyddwd) View more	-	23 Feb 2024
				Lanthanum Carbonate+Nicotinamide Placebo (Lanthanum + Nicotinamide Placebo)	fxpvjsntcy(tehrvbanps) = poqzheqprr rfqafvlndd (jcgtxfdrom, fcupjmiers - ohcqgggssg) View more
NCT03061474 (NEAT, CTgov)	Phase 2	Alzheimer Disease \| Mild cognitive disorder	46	Nicotinamide (Nicotinamide)	nbzxwkvaqc(bjztrjeceu) = nsxkukykcl ugjdkzudmg (shfxkmtmft, 14.46) View more	-	17 Oct 2023
				Placebo Comparator (Placebo)	nbzxwkvaqc(bjztrjeceu) = ljcxvbqpmw ugjdkzudmg (shfxkmtmft, 10.55) View more
NCT03419364 (CTgov)	Phase 2	Pre-Eclampsia	23	nicotinamide (Nicotinamide - Pre-eclampsia)	enjwqyjjsx(wfchnmtyad) = oggsmrdtmx tppysgkggq (kszcadcaen, 9) View more	-	08 Sep 2022
				nicotinamide (Nicotinamide - Healthy Pregnant)	enjwqyjjsx(wfchnmtyad) = utfidbnuly tppysgkggq (kszcadcaen, 9) View more
ISRCTN77237304 (ASCO2022)	Phase 2	Diffuse Large B-Cell Lymphoma	20	Study group (nicotinamide 40 mg/kgBW + carbogen 10 liter/minute during R-CHOP)	olajdombmr(snghmfndld) = kxwbutcvke vokswlyxfy (mifjrwsyke ) View more	-	02 Jun 2022
				Control group (R-CHOP)	olajdombmr(snghmfndld) = tctozqpjjp vokswlyxfy (mifjrwsyke ) View more
NCT02258074 (COMBINE TRIAL \| COMBINE \| CKD Optimal Management with Binders and Nicotinamide (COMBINE), CTgov)	Phase 2	Chronic Kidney Diseases	205	Lanthanum Carbonate+Nicotinamide (Lanthanum Carbonate + Nicotinamide)	etgevrjfis(bofaceqdbj) = ybeoonemsm qomxtnriyy (vykgbyteym, dqzlbjdsad - wfujwtxbhh) View more	-	30 Jul 2021
				Lanthanum Carbonate+Placebo (for Nicotinamide) (Lanthanum Carbonate + Nicotinamide Placebo)	etgevrjfis(bofaceqdbj) = ycgagqufrz qomxtnriyy (vykgbyteym, rlztwwxncb - rapprdymtg) View more

Translational Medicine

Boost your research with our translational medicine data.

view full example data

Deal

Boost your decision using our deal data.

view full example data

Core Patent

Boost your research with our Core Patent data.

view full example data

Clinical Trial

Identify the latest clinical trials across global registries.

view full example data

Approval

Accelerate your research with the latest regulatory approval information.

view full example data

Regulation

Understand key drug designations in just a few clicks with Synapse.

view full example data

Hiro LS Researcher

The AI Search Engine Built to Accelerate Biopharma Decisions

Search across billion-scale life sciences data to uncover signals, validate evidence, and act with confidence.

Ask any biopharma research question→

Get started for free today!

Accelerate Strategic R&D decision making with Synapse, Patsnap’s AI-powered Connected Innovation Intelligence Platform Built for Life Sciences Professionals.

Discover Synapse Data Servers

Synapse data is now integrated into the PatSnap LS Model Context Protocol (MCP) service. Customize your LLM agent now using our MCP server!

Bio

Bio Sequences Search & Analysis

Chemical

Chemical Structures Search & Analysis